Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Retrospective Assessment of Adverse Events-Related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma

NCT05874817 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT05874817
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05874817 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Retrospective Assessment of Adverse Events-Related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma
Lead sponsor
Novartis Pharmaceuticals
Phase
Observational
Overall status
Completed
Start date
May 1, 2021
Completion date
May 20, 2022
Enrollment
17,517 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma